I was looking around today and found this example:

ABT-627:
http://www.ncbi.nlm.nih.gov/pubmed/10657544?ordinalpos=1&itool=EntrezSystem2.PEntrez. Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.P ubmed_Discovery_RA&linkpos=4&log$=relatedarticles& logdbfrom=pubmed
This drug was brought to market finally--- by Abbott as Xinlay and FDA
did not approve.

If you want to follow it on Google--the press releases-- you can see.

So we many find papers, press releases showing promise for pain...but then we
never see them arrive. In this case the drug was decided as a prostate cancer
drug! (bone pain).

I remember memantine (Namenda) getting glowing reports in Europe in the late 90's on our old old board at "you know where".... everyone thought it
would work for PN here, but it is rarely if ever prescribed. I haven't seen one person recently using it for that.
http://212.17.200.140/pr02.htm

Why hasn't this happened here? It could be used off label, since it is only approved here for Alzheimer's.
Why haven't some neurologists offered this off label here to diabetics?
We never see it --- NEVER.